StartupsReuters1 day ago
Abivax nears $11 billion valuation after fundraising eases M&A pressure
1 min read
The biopharmaceutical company Abivax is approaching an estimated eleven billion dollar market capitalization as recent fundraising activities have successfully reduced merger and acquisition pressure. This financial improvement provides the firm with greater stability while it continues developing its proprietary antibody-drug conjugate therapies for oncology patients seeking advanced treatment options.
Level
Hype check
Tap to vote and see what everyone thinks.
